Riskpilot← Back to searchSign inGet full accessRosemed Holding AB
ABActiveOrg 5567844211DanderydOther financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 20090 employees
Revenue 2024
SEK 0
EBITDA margin
—
+83% vs 2023
Equity ratio
23.9%
Financial strength
Net profit 2024
SEK -31,6M
-147% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | +83% |
| Net profit | SEK -31,6M | -147% |
| Total assets | SEK 864,4M | -2% |
| Equity | SEK 206,2M | -17% |
| Employees | 0 | — |
Legal name
Rosemed Holding AB
Org number
5567844211
Legal form
Aktiebolag
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
25 juni 2009
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva investering och förvaltning av värdepapper inom det medicinska området samt investering i fastighetsbolag och därmed förenlig verksamhet.
Address
Danderyd
Email
richard.karroum@evolan.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | 13 | −6 | −46 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 0 | 13 | −6 | −46 | −8 |
| Net financials | — | 8 854 | −9 832 | −19 536 | −65 551 |
| Profit before tax | 0 | 8 866 | −9 837 | −12 820 | −25 921 |
| Tax | −0 | −0 | −3 | −5 | −5 707 |
| Net profit | 0 | 8 866 | −9 840 | −12 825 | −31 628 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 937 | 892 357 | 853 522 | 882 787 | 864 386 |
| Equity | 1 922 | 444 825 | 412 508 | 248 845 | 206 217 |
| Long-term debt | 0 | 200 000 | 138 239 | 0 | 0 |
| Short-term debt | 15 | 200 033 | 302 774 | 633 943 | 658 169 |
| Total debt | 15 | 400 033 | 441 013 | 633 943 | 658 169 |
EBITDA margin
-800000.0%
This company
15.8%
Market median
-5063391% vs market
20202024
Equity ratio
23.9%
This company
38.2%
Market median
-37% vs market
20202024
Return on equity
-15.3%
This company
18.4%
Market median
-183% vs market
20202024
Net profit margin
-3162800000.0%
This company
8.1%
Market median
-39046913680% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
3.19×
This company
0.62×
Market median
-415% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PM Chief Auditor | Chief Auditor | 2025 |
| Former (2) | ||
RN Chief Auditor | Chief Auditor | 2022 – 2025 |
UC Audit | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rosemed Holding AB 
Weflan ABBoard members of Rosemed Holding AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nicklas Kullberg | Chief Auditor | 0 companies |
| Peter Magnus Kangas | Chief Auditor | 0 companies |
| Ulla Carina Öfors | Audit | 0 companies |
| Said Richard Karroum | Board of Directors | 0 companies |
| Mona Cecilia Karroum | Deputy Board Member | 0 companies |